Researchers at Sungkyunkwan University (SKKU) in South Korea have developed what they describe as the world’s first oral nanomedicine based on the microbiome to boost anti-cancer immunity, according to Asia Research News.
The treatment delivers a metabolite produced by gut microbes via an oral nano-carrier, the outlet reports. The goal is to enhance the "stemness" of T cells, a quality that helps these immune cells persist and fight tumors more effectively during cancer immunotherapy, as detailed in a related study published in Nature.
The work was a collaboration between Korean and US researchers, The Korea Herald reports. The approach is notable because it moves away from injectable or intravenous immune treatments toward an oral formulation, which could simplify how patients receive such therapies.
According to the reporting, the nanomedicine is designed to supercharge the body’s own immune response rather than attack cancer cells directly. By improving T cell stemness, the treatment aims to make existing immunotherapies more durable and effective, though the material does not specify which cancer types were tested or whether human trials have begun.
The announcement marks an early-stage research milestone, and the underlying findings were published in a peer-reviewed journal. Still, the reporting does not include data on efficacy, safety, or timelines for clinical development.
What to watch next: whether this oral delivery platform moves from animal models into human trials, and how it might combine with existing checkpoint inhibitors in future studies.
